- Home
- MAIA
as 12-18-2024 12:39pm EST
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 52.7M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 175.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $5.99 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Guerrero Ramiro | MAIA | Director | Dec 13 '24 | Buy | $1.87 | 53,418 | $99,998.50 | 514,970 | |
| CHAOUKI STEVEN M | MAIA | Director | Nov 1 '24 | Buy | $2.51 | 22,133 | $55,553.83 | 111,024 | |
| Luput Cristian | MAIA | Director | Nov 1 '24 | Buy | $2.51 | 22,133 | $55,553.83 | 389,483 | |
| Smith Stan | MAIA | Director | Nov 1 '24 | Buy | $2.51 | 100,000 | $251,000.00 | 957,568 |
Latest MAIA Biotechnology Inc. News
MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
MAIA Biotechnology's THIO Gets US FDA Rare Pediatric Disease Designation to Treat Pediatric High-Grade Gliomas
Business Wire
2 days ago
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
Business Wire
9 days ago
MAIA Biotechnology Announces Private Placement of Approximately $950,000
Business Wire
15 days ago
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
Business Wire
a month ago
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
Business Wire
a month ago
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Business Wire
2 months ago
MAIA Biotechnology Announces $2.44 Million Private Placement
Business Wire
2 months ago
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
Compare MAIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.